SOLUTIONS FOR VIROLOGY AND VACCINE DISCOVERY

Enabling the discovery of vaccines and antiviral therapeutics against SARS-CoV-2, dengue, Zika, and other viruses

Reporter Viruses

Epitope Mapping
MAb Specificity Testing

The most extensive catalog of Reporter Virus Particles (RVPs)

Reporter Virus Particles (RVPs) are replication-incompetent pseudovirus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation

SARS-CoV-2 and Emergent Variant RVPs

SARS-CoV-2 / Variant
Catalog No. (G/L*)
Mutations
D614G
Wuhan-Hu-1
RVP-701
Reference seq (GenBank QHD43416.1)
No
D614G B.1, 20A
RVP-702
D614G
Yes
UK variant B.1.1.7, 20I/501Y.V1
RVP-706
ΔH69/V70, ΔY144, N501Y, A570D, P681H, T716I, S982A, D1118H
Yes
UK variant B.1.1.7 with E484K
RVP-717
ΔH69/V70, ΔY144, E484K, N501Y, A570D, P681H, T716I, S982A, D1118H
Yes
South African variant Δ3 B.1.351, 20H/501Y.V2
RVP-724
L18F, D80A, D215G, ΔL242/A243/L244, R246I, K417N, N501Y, E484K, A701V
Yes
South African variant B.1.351, RBD mutations only
RVP-715
K417N, E484K, N501Y
Yes
New York variant B.1.526, 20C/484K
RVP-726
L5F, T95I, D253G, E484K, A701V
Yes
Brazilian variant P.1, 20J/501Y.V3
RVP-708
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, V1176F
Yes
Nigerian/European variant B.1.525, 20A/439K
RVP-723
Q52R, ΔH69/V70, ΔY144, E484K, Q677H, F888L
Yes
Californian variant B.1.427/B.1.429, 20C/452R
RVP-713
S13I, W152C, L452R
Yes

*All RVPs are available with a GFP (G) or luciferase (L) reporter. Please add G/L to the catalog number when ordering to indicate the preferred reporter gene. 

RVPs Coming Soon

SARS-CoV-2 Variant
Catalog No. (G/L)
Mutations
D614G
UK/Nigerian variant B.1.1.318, 20B/484K
RVP-728
T95I, ΔY144, E484K, P681H, D796H
Yes
Indian variant B.1.617, RBD mutations only (“double mutant”)
RVP-727
L452R, E484Q
Yes
Indian variant B.1.617
RVP-730
G142D, E154K, L452R, E484Q, P681R, Q1071H
Yes

Custom SARS-CoV-2 RVP variants and RVPs from our library of 1,200 alanine spike mutants are available upon request. Please contact us for pricing.

More SARS Variant RVPs

SARS-CoV-2 RVPs / Variants
Catalog No. (G/L)
Mutations
D614G
US/Ohio strain, N501Y 20G/501Y
RVP-710
N501Y
Yes
S477N (Australian/European variant)**
RVP-711
S477N
Yes
COHD15, US/Ohio variant
RVP-712
Q677H, L938F
Yes
Robin* 20G/677H
RVP-718
Q677H
Yes
Pelican* 20G/677P
RVP-719
Q677P
Yes
Quail* 20B/677H
RVP-721
Q677H, T732S
Yes
Mockingbird* 20A/677H
RVP-722
G142S, E180V, Q677H
Yes
E484K
RVP-709
E484K
Yes
N439K
RVP-703
N439K
No
N439K/D614G 20A/439K
RVP-704
N439K
Yes
Danish mink “cluster 5”
RVP-705
ΔH69/V70, Y453F, I692V, M1229I
No
US variant N679S***
RVP-725
N679S
Yes
South African variant B.1.351, 20C/501Y.V2
RVP-707
L18F, D80A, D215G, L242H, R246I, K417N, N501Y, E484K, A701V
Yes
South African variant Δ2 B.1.351, 20H/501Y.V2
RVP-714
L18F, D80A, D215G, ΔL242/A243, R246I, K417N, N501Y, E484K, A701V
Yes
SARS-CoV-1 Urbani
RVP-801
N/A
N/A
MERS-CoV HCoV-EMC (GFP only)
RVP-901
N/A
N/A

* Described in Hodcroft et al., 2021

** Described in Hodcroft et al., 2020

***Identified in a newborn with high viral load (LoTempio et al., 2021)

See RVP application notes

Negative Control RVPs

Virus
Strain
Catalog No. (G/L)
VSV
Indiana
RVP-1001

VSV RVPs can be used as a neutralization control to assess non-specific effects on infectivity or signal. These RVPs display the vesicular stomatitis virus glycoprotein, resulting in broad tropism, and show a single round of infectivity with numerous cell types, including the transgenic ACE2 cells provided with RVPs.

Cell Lines

Transgenes
Expression
Clonality
Origin Cell Line
Catalog No.
hsACE2
Stable
Monoclonal
HEK 293T
C-HA102
hsACE2, hsTMPRSS2
Stable
Monoclonal
HEK 293T
C-HA201

Flavivirus RVPS

Virus
Strain
Catalog No. (G/L)
Dengue Virus 1
WestPac
RVP-101
Dengue Virus 2
S16803
RVP-201
Dengue Virus 3
CH53489
RVP-301
Dengue Virus 4
TVP360
RVP-401
Zika Virus
SPH2015
RVP-601

Integral Molecular’s RVPs are produced under stringent quality-controlled conditions

With two decades of virology experience, Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials

See RVP application notes

Frequently Asked Questions

Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery and antibody discovery against viral targets.

RVPs incorporate virus-specific prM/E proteins and are antigenically equivalent to live wildtype viruses. They contain a modified RNA genome so they are safe and replication incompetent.

RVPs are useful for high-throughput infectivity and neutralization assays. They are an efficient alternative to plaque assays.

Luciferase or GFP is used for quantitative read out.

Ready To Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.

Or call (215) 966-6061